Autopsy report · NCT01317966

Recombinant Human Interleukin-11 Combination Low-dose Rituximab in Immune Thrombocytopenia

“No eligible patients were enrolled.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Sponsor

Ming Hou

Sponsor type

University, hospital or other

Conditions

Purpura, Thrombocytopenic, Idiopathic

Interventions

rhIL-11

Participants

0

Sites

1

Countries

China

Trials that died the same way

• Recombinant Human Thrombopoietin (rhTPO) Combining Rituximab Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)
  “No eligible patient was enrolled.” (97% match in meaning)
• Use of the INAMED LAPBAND System to Reduce BMI's in Obese Renal Failure Patients
  “No patients were enrolled.” (96% match in meaning)
• Energy Expenditure and Gastric Bypass Surgery
  “no patients enrolled.” (95% match in meaning)
• Effects of Atomized Dexmedetomidine on Lung Function in Patients With Chronic Obstructive Pulmonary Disease
  “no patient enrolled.” (92% match in meaning)
• Tolerability, Safety and Activity of a Muscle Relaxant Molecule IDN5243 in Patients With Low Back Pain
  “No patients enrolled in the study.” (89% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.